About US
Contact us
-
Novo Nordisk's weight loss drug Wegovy to run short amid contract manufacturer hiccupDemand for Novo Nordisk’s obesity medicine Wegovy is high, but a manufacturing hitch with one of the Danish company’s partners has put near-term supply in jeopardy. Novo Nordisk on Friday2021/12/24
-
With Sanofi's mighty Dupixent chasing behind, Takeda's Eohilia suffers FDA rejection after mysterious delayAnother piece of bad news has hit Takeda’s Wave 1 pipeline, dealing a blow to the Japanese pharma’s plan to deliver a boost to near-term sales. After missing a decision deadline in April, the FDA has2021/12/24
-
2022 forecast: Biopharma M&A lags in 2021. Will drugmakers still look for bolt-on deals or large transactions?In contrast to the bustling dealmaking by medtech and life sciences service businesses, merger and acquisition activity by drugmakers went largely quiet in 2021. But after all the slim-downs, biophar2021/12/22
-
Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavirA second major HIV prospect has been put on hold, this time from Gilead Sciences. But unlike the recent halt on Merck's drug islatravir, which was related to a drop in trial patients' immune cell cou2021/12/22
-
2022 forecast: With omicron extending the pandemic, how will biopharma respond to COVID?Think back to this time last year. Remember the uncertainty the COVID-19 pandemic posed? Well, thanks to omicron, here we are again, asking many of the same questions and with renewed anxiety about t2021/12/20
-
2022 forecast: Cell, gene therapy makers push past regulatory, payer hurdles to set up high hopes for next yearFor developers of cell and gene therapies, the path to market often seems to be marred with potholes. The FDArejectedBioMarin Pharmaceutical’s gene therapy to treat hemophilia A in 2020, citing the n2021/12/20
-
Novartis launches $15B share buyback after huge windfall from Roche stake sale—but M&A is still in the cardsNovartis has found a way to spend the big pile of cash—at least $15 billion of it—the drugmaker received from selling a large stake in Swiss rival Roche. Novartis isinitiatinga share buyback campa2021/12/17
-
Biogen hits the gas pedal on Aduhelm confirmatory trial, hoping to deliver results in 2026Biogen is looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s disease drug Aduhelm out in four years, as the fate of this drug, and Biogen itself, rests in the ba2021/12/17
-
As part of $800M investment, Pfizer opens gene therapy facility in NC for early-stage productionPfizer is betting big on gene therapy development and manufacturing. And to that end, it is centralizing its operations in—where else—North Carolina. These days in the biopharma industry,2021/12/15
-
In its old age, Bristol Myers' Orencia becomes first drug approved for preventing graft-versus-host diseaseIn its twilight, Bristol Myers Squibb’s Orencia is putting together an impressive second act. The rheumatoid arthritis drug—originally approved in 2005—got a nice bump in 2017 with an approval for ps2021/12/15